Nausea on Foundayo™

The first row of Table 1

Section 6.1 pools Trials 1 and 2, two double-blind studies in adults with obesity or overweight, one without and one with type 2 diabetes, lasting up to 72 weeks ^[1]. They used an investigational formulation whose doses the label reports as the equivalent Foundayo™ strengths. Table 1 lists reactions seen in at least 5% of treated adults and more often than on placebo, and nausea comes first ^[1]. The Medication Guide also puts nausea at the head of its list of common side effects ^[2].

Outside the US the paperwork is thinner. The European Medicines Agency’s committee recommended approval on 15 October 2026 and named nausea, vomiting and diarrhoea as the most common side effects, but no EMA product information with frequency bands exists yet ^[3]. A search of Health Canada’s Drug Product Database on 20 October 2026 found no Foundayo™ or orforglipron entry ^[4].

A jump, then a plateau

The shape of these numbers is worth a second look. Going from 5.5 mg to 9 mg added eight percentage points, while going from 9 mg to 17.2 mg added only one ^[1]. So in this pool the largest dose was not much worse for nausea than the middle one. Each figure counts people who reported nausea at least once over the whole trial, not people who felt sick on any given day.

Placebo also produced nausea in one person in ten ^[1]. That baseline is a reminder that some queasiness during a long weight trial would have happened anyway; the difference between the groups is the part linked to the medicine.

All stomach and bowel reactions together were reported by 60% to 69% of people on Foundayo™, against 37% on placebo. Of those who had them, 60% called them mild, 36% moderate and 4% severe ^[1]. They led 3% of people on 5.5 mg and 6% on each higher dose to stop treatment, compared with 0.7% on placebo; nausea is not given a stopping rate of its own ^[1].

Pulling the two weight trials apart

The registry page for each trial shows what the pooled table blends. Both list only non-serious events that reached 5% in at least one group, and neither lists nausea among its serious events ^[5][6]. ATTAIN-1 and ATTAIN-2 tested trial doses of 6, 12 and 36 mg, which the label reports as 5.5, 9 and 17.2 mg ^[1].

• Two shapes hide under the pooled plateau. In adults without diabetes, nausea peaked at the middle dose; in adults with type 2 diabetes it began lower on 5.5 mg and rose with each dose ^[5][6].
• The published reports call the stomach events mostly mild to moderate, and the ATTAIN-2 paper says they occurred mainly during dose escalation ^[8][9].
• ACHIEVE-3 is the only head-to-head trial against another oral GLP-1 medicine. It was open label, so participants knew which tablet they took, which can shape what they report, and it was run in type 2 diabetes, a use the US label does not cover ^[7][10].
• In that trial stomach events overall were reported by 59% and 58% on orforglipron against 37% and 45% on oral semaglutide, and more people stopped orforglipron because of side effects ^[10].

Why the stomach reacts

Backed by the label: Foundayo™ activates GLP-1 receptors, which the label places in brain regions that regulate appetite, and it delays stomach emptying, most after the very first dose and less as time goes on ^[1]. The dose ladder follows from this; section 2.1 says the slow start is there to reduce stomach and bowel reactions ^[1].

Suggested but not measured: MedlinePlus lists slow emptying of the stomach among causes of nausea ^[11], which fits the label finding, but no orforglipron study has tied a person’s emptying speed to their nausea. Nor has anyone tested whether meal size or fat content changes nausea on the tablet; the label says only that food has no clinically relevant effect on drug levels ^[1].

General knowledge: MedlinePlus now names glutides, medicines used for diabetes or obesity, among the medicines that bring on nausea and vomiting ^[11]. Orforglipron is a non-peptide molecule ^[10], but it acts on the same receptor.

When the queasiness has another source

A new tablet is an easy suspect, yet MedlinePlus lists many everyday causes of nausea: stomach or bowel infections, food poisoning, reflux, migraine, motion sickness, pregnancy, severe pain such as from kidney stones and heavy marijuana use ^[11]. Cleveland Clinic adds stress and anxiety, vertigo and sensory triggers such as strong smells ^[12]. MedlinePlus also names more serious problems in which nausea can be an early warning, including appendicitis, a blocked bowel and ulcers ^[11].

Two of those deserve a closer look on this tablet. Pregnancy, because the Medication Guide says Foundayo™ may harm an unborn baby and asks you to tell your provider if you become pregnant ^[2]. Reflux, because gastroesophageal reflux disease appears in Table 1 in 6% to 7% on the tablet against 2% on placebo ^[1].

What general sources say eases nausea

MedlinePlus suggests drinking small amounts of clear liquids often and changing what you eat ^[11]. Cleveland Clinic lists avoiding the foods or drinks that set you off, eating smaller meals more often and more slowly, choosing plain, bland foods, not exerting yourself straight after eating and trying plain crackers or ginger ^[12]. None of these has been tested with orforglipron.

Anti-sickness medicines are a question for a pharmacist. Cleveland Clinic notes that over-the-counter remedies are not automatically safe and are usually not meant for frequent or long-term use ^[12]. The Foundayo™ label adds that the tablet slows stomach emptying and can affect how other medicines taken by mouth are absorbed ^[1], and the Medication Guide asks you to tell your provider about every medicine, including non-prescription ones ^[2].

The label takes away one lever people often reach for: the tablet is taken with or without food, so moving it to or from a meal is not something the label ties to nausea ^[1]. Ask your prescriber before changing how you take it.

Steps, gaps and restarts

Section 2.1 starts Foundayo™ at 0.8 mg once daily and moves to 2.5 mg and then 5.5 mg, each step after at least 30 days. Later steps to 9 mg, 14.5 mg and 17.2 mg depend on response and tolerability, decided by the prescriber ^[1]. The label does not say how many days nausea lasts after a step for any one person.

Missed tablets: a missed dose is taken as soon as possible, and never two in one day ^[1][2]. After seven or more missed days in a row, the label restarts escalation at a lower dose to reduce stomach reactions, and the Medication Guide asks you to call your provider about how to restart ^[1][2].

Other medicines: strong CYP3A4 inhibitors raise orforglipron levels, which section 7.1 says may increase the risk of side effects. The label caps the dose at 9 mg with them, so your prescriber needs your full medicine list ^[1].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.